ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1082

Outcomes of Methotrexate as an Initial Induction and Maintenance Regimen for Localized Granulomatosis with Polyangiitis: A Retrospective Review

Pratyusha Banik1, Marcia Friedman2, Daniela Ghetie3, Dongseok Choi4 and Margaret Brophy1, 1Oregon Health & Science University, Portland, OR, 2Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR, 3Oregon Health & Science University, Division of Arthritis and Rheumatic Diseases, Lake Oswego, OR, 4OHSU-PSU School of Public Health, Portland, OR

Meeting: ACR Convergence 2022

Keywords: ANCA, ANCA associated vasculitis, Granulomatosis with Polyangiitis (GPA), Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: While there is established data regarding the induction and maintenance treatment of systemic or organ threatening granulomatosis with polyangiitis (GPA), there is limited data regarding the outcomes of methotrexate (MTX) as an initial induction and maintenance regimen for localized GPA.

Methods: A retrospective chart review was performed of all patients at Oregon Health & Science University with a diagnosis of localized GPA (confirmed by a rheumatologist) treated initially with MTX and glucocorticoids as induction and MTX as maintenance treatment. Exclusion criteria were systemic involvement (glomerulonephritis, symptomatic pulmonary infiltrates, alveolar hemorrhage, pachymeningitis, mononeuritis multiplex, cardiac or mesenteric involvement), prior induction with rituximab (RTX) or CYC, and insufficient documentation in medical records to monitor response. Data were abstracted from charts at the initial visit when MTX was first prescribed (Table 1), and at 3, 6, and 12 month follow ups. At each visit, clinical data were collected including a Birmingham Vasculitis Activity Score (BVAS, version 3) calculated based on chart documentation, current therapy (MTX/corticosteroid doses), treatment decisions (continue or escalate therapy and reasons for doing so), and disease status (remission, persistent disease, localized organ threatening disease, or progression to systemic involvement). Remission was defined as a BVAS score of 0 on MTX and ≤5 mg prednisone daily. Persistent disease was defined as a BVAS score of greater than 0 but no new/worsening disease. Localized organ threatening disease was defined as having localized worsening symptoms placing tissues or patients at risk of permanent damage. The primary outcomes were remission rate at 12 months of MTX therapy, rate of requiring RTX or CYC, and rate of progression to systemic disease prior to 12 months.

Results: A total of 31 patients were included in the analysis (Figure 1). The most common clinical manifestation was sinusitis (Figure 2). 15/31 patients (48%) patients were in remission at one year on MTX and prednisone ≤ 5 mg/day. 12/31 patients (39%) required RTX or CYC prior to one year; 6 for organ threatening localized disease (1 each for necrotizing scleritis, progressive tracheal stenosis, retro-orbital disease, saddle nose deformity, diplopia, and 2 for hearing loss), 3 for persistently active localized disease, and 3 (9.5%) for progression to systemic disease. Of the 15 patients who achieved remission on MTX at one year, 3 patients required RTX after the 12-month mark; 1 developed glomerulonephritis, 1 developed organ threatening disease, and 1 had persistent disease requiring repeated high dose prednisone.

Conclusion: In this real-world retrospective analysis, among patients with localized GPA treated initially with MTX and glucocorticoids, 48% achieved remission at one year of therapy. 9.5% patients developed systemic disease prior to one year of therapy. MTX can be a highly effective initial therapy for some patients with localized GPA, however many patients will ultimately require escalation to rituximab or cyclophosphamide.

Supporting image 1

Table 1

Supporting image 2

Figure 1

Supporting image 3

Figure 2


Disclosures: P. Banik, None; M. Friedman, revolo; D. Ghetie, None; D. Choi, None; M. Brophy, None.

To cite this abstract in AMA style:

Banik P, Friedman M, Ghetie D, Choi D, Brophy M. Outcomes of Methotrexate as an Initial Induction and Maintenance Regimen for Localized Granulomatosis with Polyangiitis: A Retrospective Review [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/outcomes-of-methotrexate-as-an-initial-induction-and-maintenance-regimen-for-localized-granulomatosis-with-polyangiitis-a-retrospective-review/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/outcomes-of-methotrexate-as-an-initial-induction-and-maintenance-regimen-for-localized-granulomatosis-with-polyangiitis-a-retrospective-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology